NASDAQ:STTK Shattuck Labs Q4 2025 Earnings Report $6.79 -0.17 (-2.44%) As of 04:00 PM Eastern ProfileEarnings HistoryForecast Shattuck Labs EPS ResultsActual EPS-$0.12Consensus EPS -$0.12Beat/MissMet ExpectationsOne Year Ago EPSN/AShattuck Labs Revenue ResultsActual Revenue($1.00) millionExpected Revenue$0.17 millionBeat/MissMissed by -$1.17 millionYoY Revenue GrowthN/AShattuck Labs Announcement DetailsQuarterQ4 2025Date3/5/2026TimeBefore Market OpensConference Call DateThursday, March 5, 2026Conference Call Time6:30AM ETUpcoming EarningsShattuck Labs' Q3 2026 earnings is estimated for Tuesday, November 10, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Shattuck Labs Earnings HeadlinesShattuck Labs Announces Participation in Upcoming September Investor ConferencesSeptember 2 at 4:05 PM | globenewswire.comShattuck Labs: A Receptor-Side Bet On The TL1A BoomSeptember 1 at 8:00 AM | seekingalpha.comDo NOT Buy the Next $2 Trillion IPO Before Reading ThisAnthropic is reportedly preparing to file its IPO prospectus shortly after Labor Day, with a potential valuation as high as 2 trillion dollars. Before the headlines and hype hit, Michael Robinson says there is something investors should understand first, what he calls the Big IPO Lie. He has uncovered a different way to look at Anthropic's move ahead of its public debut.September 4 at 1:00 AM | Weiss Ratings (Ad)Shattuck Labs (NASDAQ:STTK) Upgraded at TD CowenAugust 27, 2026 | americanbankingnews.comShattuck Labs Advances SL-325 Crohn’s Trial Toward a Key Value MilestoneAugust 12, 2026 | tipranks.comShattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business HighlightsAugust 11, 2026 | markets.businessinsider.comSee More Shattuck Labs Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Shattuck Labs? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Shattuck Labs and other key companies, straight to your email. Email Address About Shattuck LabsShattuck Labs (NASDAQ:STTK) (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier. The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities. Preclinical studies have demonstrated that vaccinated animals produce robust anti‐fentanyl antibody titers and are protected against lethal and sublethal fentanyl challenges. Shattuck Labs is advancing its vaccine candidate through IND‐enabling studies and plans to initiate first‐in‐human trials to evaluate safety, immunogenicity, and its potential to block the psychoactive effects of fentanyl. Founded in 2017, Shattuck Labs was established to address the growing public health crisis posed by opioid misuse and overdose. The company leverages insights from immunology and vaccinology, collaborating with academic partners and contract manufacturing organizations to streamline development and scale up production. Shattuck Labs serves the U.S. market and is preparing for broader geographic reach as its clinical programs progress. Shattuck Labs is led by Chief Executive Officer Craig H. Wheeler, who brings extensive experience in biopharmaceutical R&D and commercial strategy. The management team includes experts in vaccine formulation, regulatory affairs, and translational medicine. Through its focused pipeline and innovative platform, Shattuck Labs aims to pioneer a new class of non‐addictive, immunotherapeutic treatments for substance use disorders.View Shattuck Labs ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Snowflake’s AI Momentum Is Forcing a Fresh Look at the StockAeroVironment’s $465 Million Army Laser Win Expands Its Counter-Drone OpportunityFB Financial's Southern Expansion and Buybacks Drive Analyst OptimismRetail Earnings Just Exposed a Bigger Divide in the U.S. Consumer EconomyAccelerant’s Take-Private Deal Raises a Bigger Question for Insurance StocksDefense Stocks Are Pulling Back as Their Navy Tailwinds Get StrongerThe Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story Upcoming Earnings Adobe (9/10/2026)Oracle (9/10/2026)FedEx (9/17/2026)Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
